Literature DB >> 20339315

Immunomodulatory effects of VEGF: Clinical implications of VEGF-targeted therapy in human cancer.

Giovanni Vitale1, Alessandra Dicitore, Davide Gentilini, Francesco Cavagnini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20339315     DOI： 10.4161/cbt.9.9.11691

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  6 in total

1.  Synthesis and in vitro evaluation of [18F](R)-FEPAQ: a potential PET ligand for VEGFR2.

Authors:  Jaya Prabhakaran; Victoria Arango; Vattoly J Majo; Norman R Simpson; Suham A Kassir; Mark D Underwood; Hanish Polavarapu; Jeffrey N Bruce; Peter Canoll; J John Mann; J S Dileep Kumar
Journal:  Bioorg Med Chem Lett       Date:  2012-06-07       Impact factor: 2.823

2.  Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.

Authors:  Cirino Botta; Vito Barbieri; Domenico Ciliberto; Antonio Rossi; Danilo Rocco; Raffaele Addeo; Nicoletta Staropoli; Pierpaolo Pastina; Giulia Marvaso; Ignazio Martellucci; Annamaria Guglielmo; Luigi Pirtoli; Pasquale Sperlongano; Cesare Gridelli; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri; Pierpaolo Correale
Journal:  Cancer Biol Ther       Date:  2013-06       Impact factor: 4.742

Review 3.  A perspective on the role of class III semaphorin signaling in central nervous system trauma.

Authors:  Vasil Mecollari; Bart Nieuwenhuis; Joost Verhaagen
Journal:  Front Cell Neurosci       Date:  2014-10-27       Impact factor: 5.505

Review 4.  Extracellular Matrices to Modulate the Innate Immune Response and Enhance Bone Healing.

Authors:  Andrés García-García; Ivan Martin
Journal:  Front Immunol       Date:  2019-09-20       Impact factor: 7.561

5.  The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients.

Authors:  Butuo Li; Shijiang Wang; Cheng Li; Meiying Guo; Yiyue Xu; Xindong Sun; Jinming Yu; Linlin Wang
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

Review 6.  Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Authors:  Vito Longo; Oronzo Brunetti; Antonio Gnoni; Antonella Licchetta; Sabina Delcuratolo; Riccardo Memeo; Antonio Giovanni Solimando; Antonella Argentiero
Journal:  Medicina (Kaunas)       Date:  2019-10-17       Impact factor: 2.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.